Dianthus Therapeutics (DNTH) Non-Current Deferred Tax Liability (2017 - 2022)

Dianthus Therapeutics' Non-Current Deferred Tax Liability history runs 4 years deep, the most recent figure standing at $949000.0 for Q4 2022.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 18.26% year-over-year to $949000.0 in Q4 2022; TTM through Dec 2022 was $949000.0, a 18.26% decrease from a year earlier, with the FY2022 full-year figure at $949000.0, down 18.26% from the prior year.
• Non-Current Deferred Tax Liability retreated to $949000.0 in Q4 2022 per DNTH's latest filing, from $1.2 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $1.2 million in Q4 2021 and bottomed at $361000.0 in Q4 2018.
• The 3-year median for Non-Current Deferred Tax Liability is $949000.0 (2022), against an average of $823666.7.
• Across the five-year window, Non-Current Deferred Tax Liability soared 684.78% in 2018 and retreated 18.26% in 2022, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $361000.0 in 2018, then jumped by 221.61% to $1.2 million in 2021, then decreased by 18.26% to $949000.0 in 2022.
• Per Business Quant, the three latest DNTH Non-Current Deferred Tax Liability figures stand at $949000.0 (Q4 2022), $1.2 million (Q4 2021), and $361000.0 (Q4 2018).